Avacc 10
Alternative Names: Avacc-10; COVID 2019 vaccine - Intravacc; CovOMV - IntravaccLatest Information Update: 05 Apr 2024
Price :
$50 *
At a glance
- Originator Intravacc
- Class COVID-19 vaccines; Subunit vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 15 Jan 2024 Intravacc completes a phase I trial in COVID-2019 infections (Prevention) in Australia (Intranasal) (NCT05604690)
- 01 Dec 2022 Avacc 10 is available for licensing as of 01 Dec 2022. https://www.intravacc.nl/vaccine-products/
- 29 Nov 2022 Phase-I clinical trials in COVID-2019 infections (Prevention) in Australia (Intranasal) (NCT05604690)